NCT06888622Completed
BLAZE-Limiting Approach in NMOSD
Eculizumab for Blaze-limiting Approach in NMOSD: A Prospective Study
Source: ClinicalTrials.gov · Last updated 21 Mar 2025
Brief summary (registry, in English)
This is an observational cohort study based on data from the hospital-based NMOSD registry (Chinese Medical Research Registration Number MR-31-22-008563; ChiCTR2000030651). Between October 2023 (when eculizumab was approved for NMOSD in China) and February 2025, 26 consecutive patients with AQP4-IgG-positive NMOSD received eculizumab, and 9 of them were included in this study.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 9 (actual)
- First submitted
- 14 Mar 2025
- Start date
- 1 Oct 2023
- Primary completion date
- 1 Mar 2025
- Lead sponsor
- Huashan Hospital
- Diseases
- Neuromyelitis optica (NMOSD)
- NCT number
- NCT06888622
What you commit to
- Study type: Observational
- Participants enrolled: 9
- From 1 Oct 2023 to the primary completion date, 1 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with unresolved Neisseria meningitidis infection or severe infections that preclude the use of immunotherapy;
- Patients with severe comorbidities (such as heart failure, respiratory failure, severe hepatic or renal dysfunction, etc.);
Lab values
- Patients with incomplete records of clinical symptoms and signs, as well as insufficient data on serum marker tests in their medical records.
Who the study is looking for
- (1)Patients have been diagnosed with NMOSD and tested seropositive for AQP4 antibody; (2) Age ≥ 18 years; (3) Received eculizumab during an acute phase of NMOSD, defined as within 30 days of attack onset； (4) Adherence to an 8-week follow-up from eculizumab initiation.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Huashan Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.